Miniatura

Fitxers

737102.pdf (837.36 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-07-06

Llicència de publicació

cc by- nc-nd (c) Díaz González, Álvaro et al., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/200305

Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/ueg2.12111

Resum

Background: Despite atezolizumab and bevacizumab (A + B) is currently the first-line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. Objective: To characterize the early diarrhoea development as prognostic factor in 344 HCC patients. Methods: The development of early diarrhoea in sorafenib treatment defined as patients who developed diarrhoea and needed dose modification within the first 60 days of treatment (e-diarrhoea) and 3-grouping variables were analysed: Patients with e-diarrhoea, patients who developed diarrhoea after the first 60 days of treatment (L-diarrhoea) and patients that never developed diarrhoea (never diarrhoea). Results: The median overall survival in sorafenib treated patients was significantly different across groups (6.8 months for e-diarrhoea, 26.7 months for L-diarrhoea and 13.3 months for never-diarrhoea). The emergence of e-diarrhoea was associated with poor outcomes (hazard ratio [HR] 1.84 [95%CI 1.15-2.95]), while there was no increased/decreased risk of dismal evolution in patients with L-diarrhoea (HR 0.66 [95%CI 0.42-1.03]). Conclusion: The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies.

Matèries

Hepatologia, Cèl·lules canceroses, Càncer de fetge, Diarrea, Resistència als medicaments, Anàlisi de supervivència (Biometria), Proteïna-tirosina-fosfatasa, Proteïnes quinases, Inhibició

Matèries (anglès)

Hepatology, Cancer cells, Liver cancer, Diarrhea, Drug resistance, Survival analysis (Biometry), Protein-tyrosine phosphatase, Protein kinases, Inhibition

Citació

Col·leccions

Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

DÍAZ GONZÁLEZ, Álvaro, SAPENA, Victor, BOIX I FERRERO, Loreto, TORRES, Ferran, SANDUZZI ZAMPARELLI, Marco, DA FONSECA, Leonardo g., LLARCH, Neus, ISERTE, Gemma, GUEDES, Cassia, MUÑOZ MARTÍNEZ, Sergio gabriel, DARNELL, Anna, BELMONTE, Ernest, RIMOLA GIBERT, Jordi, FORNER, Alejandro, AYUSO COLELLA, Carmen, BRUIX TUDÓ, Jordi, REIG, María. Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. _United European Gastroenterology Journal_. 2021. Vol. 9, núm. 9, pàgs. 655-661. [consulta: 24 de gener de 2026]. ISSN: 2050-6406. [Disponible a: https://hdl.handle.net/2445/200305]

Exportar metadades

JSON - METS

Compartir registre